The study will measure the difference of ketoprofen amount found in the bloodstream, when topically applied under different conditions along with the study of the dose percentage when administered during oral delivery.
Imprimis has selected Novum Pharmaceutical Research Services and PPD Laboratories to conduct the studies on 40 healthy human subjects.
Impracor has been designed to deliver ketoprofen on the affected area using topical-delivery platform, Accudel, a patented property of Imprimis.
Imprimis chief medical officer Joachim Schupp said the company believes that the study is a step forward to understand the influence of different conditions on the absorption of topical ketoprofen.
Imprimis CEO Mark Baum said, "We are pleased to achieve an important milestone for our company, which we expect to be the first of many such advances as we pursue FDA approval of our lead pain and anti-inflammatory product, Impracor™ and consider other potential product candidates utilizing our unique Accudel™ topical drug-delivery platform as we implement our business model."
Ketoprofen is presently available in an oral formulation in the US market alone, according to Imprimis.
Going forward, Imprimis is planning to redesign Accudel delivery platform for all the FDA approved drugs.